TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8131394

Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard removal technique
Number of subjects: 76
Study: 3299567

Group type: EXPERIMENTAL
Intervention: Ambroxol retard (75 mg)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 29065710

Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing Lactobacillus strains (125 g, twice daily for 4 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Yoghurt drink containing Lactobacillus strains
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (125 g chemically acidified milk, twice daily for 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 27609384

Group type: EXPERIMENTAL
Intervention: Sof‐lex discs system
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Super‐snap system
Number of subjects: 150

Group type: COMPARATOR
Intervention: diamond bur and rubber cup
Number of subjects: 150
Study: 26346155

Group type: EXPERIMENTAL
Intervention: bivalent HPV vaccination (n=3727)
Number of subjects: 7466

Group type: COMPARATOR
Intervention: hepatitis A vaccine (n=3739)
Number of subjects: 7466

Group type: COMPARATOR
Intervention: unvaccinated cohort (n=2836)
Number of subjects: 7466
Study: 23607963

Group type: EXPERIMENTAL
Intervention: Topical vitamin E once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Emollient once daily
Number of subjects: 80
Study: 21555965

Group type: EXPERIMENTAL
Intervention: Lateral needle approach
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medial needle approach
Number of subjects: 80
Study: 18794002

Group type: EXPERIMENTAL
Intervention: Restorative proctocolectomy
Number of subjects: 0
Study: 16364231

Group type: EXPERIMENTAL
Intervention: Alarm timings in FCWS at different driving speeds (40, 60, 70 mile/h) and time headways (1.7 and 2.2 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late alarms presented after braking actions initiated
Number of subjects: 0
Study: 15804075

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH) pretreatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 16
Study: 11041396

Group type: EXPERIMENTAL
Intervention: rBPI21 (2 mg/kg over 30 min followed by 2 mg/kg over 24 h)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo (0.2 mg/mL human albumin solution)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: rBPI21
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 8769511

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) oral rinse
Number of subjects: 353
Study: 8335049

Group type: EXPERIMENTAL
Intervention: Single instillation of Epirubicin immediately after TUR
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Cold forceps biopsy and fulguration
Number of subjects: 501

Group type: COMPARATOR
Intervention: Visual inspection by urologist
Number of subjects: 501
Study: 2868163

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 0
Study: 29094806

Group type: EXPERIMENTAL
Intervention: Algorithm-based approach for the diagnosis and management of FGIDs (ADAM-FGID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 27090649

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) high assist
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) high assist
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV) targeting large V T (15 mL × kg(‐1))
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) low assist
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) low assist
Number of subjects: 23
Study: 24966672

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1266
Study: 22142341

Group type: EXPERIMENTAL
Intervention: Pre-coseasonal SLIT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous SLIT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19717399

Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TNF inhibitors + methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19099008

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs)
Number of subjects: 5822
Study: 15886247

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/d
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Metformin 2550 mg/d
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 83
Study: 12957432

Group type: EXPERIMENTAL
Intervention: Exercise training (3 sessions per week, 60 minutes each, for 4 months)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 16

Group type: COMPARATOR
Intervention: Trained normal controls
Number of subjects: 16
Study: 11007078

Group type: EXPERIMENTAL
Intervention: Percutaneous dilational tracheostomy (PDT) performed in the operating room by a head and neck surgeon (group 1)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Standard operative tracheostomy performed by the same surgeon (group 2)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Bedside PDT by critical care physicians (group 3)
Number of subjects: 311
Study: 8874243

Group type: EXPERIMENTAL
Intervention: Smoked cocaine base (38.5 +/- 2.3 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: i.v. cocaine HCl (30.0 +/- 2.0 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Smoked placebo (2.3 +/- 0.9 mg cocaine base)
Number of subjects: 14

Group type: COMPARATOR
Intervention: i.v. saline solution placebo
Number of subjects: 14
Study: 1509861

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin b.i.d. for 5 days
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 6714054

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cimetidine and antacid suspension
Number of subjects: 10
Study: 30919249

Group type: EXPERIMENTAL
Intervention: Perindopril/Amlodipine SPC (3.5/2.5 mg to 14/10 mg)
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Irbesartan (150 mg to 300/25 mg)
Number of subjects: 1617
Study: 29301123

Group type: COMPARATOR
Intervention: 1,426 ppm F (control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Zn-A (0.3% ZnCl2, 1,426 ppm F)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Zn-B (as Zn-A, with high-foaming surfactants)
Number of subjects: 62
Study: 27420976

Group type: EXPERIMENTAL
Intervention: Modified Da Chengqi granules
Number of subjects: 77
Study: 23999996

Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for minimum movement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for maximum movement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Individual-based hemodynamic response function (ibHRF) model for post-fatigue maximum movement
Number of subjects: 9

Group type: COMPARATOR
Intervention: Post-fatigue maximum movement compared to maximum movement
Number of subjects: 9
Study: 22562516

Group type: EXPERIMENTAL
Intervention: Children in Northern Ireland aged 12 to 13 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children in Sydney aged 12 to 13 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children in Northern Ireland (both ages)
Number of subjects: 0
Study: 19937046

Group type: EXPERIMENTAL
Intervention: SCH486757 100 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Codeine 30 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 91
Study: 18327795

Group type: EXPERIMENTAL
Intervention: Meniscectomy patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 105
Study: 15825069

Group type: EXPERIMENTAL
Intervention: Ornidazole 1 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12442930

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% 30 mL (+epinephrine 5 microg mL(‐1))
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% 15 mL (+epinephrine 5 microg mL(‐1))
Number of subjects: 40
Study: 10359905

Group type: EXPERIMENTAL
Intervention: Goat's milk (GM)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cow's milk (CM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Soy formula (Isomil, Abbott, Italy)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CAP inhibition tests with CM or GM
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Immunoblotting inhibition assays with CM and GM
Number of subjects: 26
Study: 7718316

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen in patients with skeletal metastases
Number of subjects: 318
Study: 1850870

Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy with interdisciplinary communication among therapists (surgeon, radiotherapist, oncologist) and pathologist.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-preserving therapy under unfavorable prerequisites for cosmetically satisfactory results.
Number of subjects: 0
Study: 6345013

Group type: EXPERIMENTAL
Intervention: Mefloquine 1000 mg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mefloquine 750 mg
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mefloquine 500 mg
Number of subjects: 147
Study: 30628088

Group type: EXPERIMENTAL
Intervention: Adjunctive azithromycin (500 mg for 3 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adjunctive amoxicillin plus metronidazole (500 mg AMX plus 400 mg MTZ three times per day for 7 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 38
Study: 28110355

Group type: EXPERIMENTAL
Intervention: Vibrations-Dive (VD) group
Number of subjects: 26

Group type: COMPARATOR
Intervention: Diving (D) group (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vibration (V) protocol group
Number of subjects: 26
Study: 26342295

Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to increase HIV testing rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to increase ART engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prescriber-focused intervention to optimize ART retention
Number of subjects: 0
Study: 23446085

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 36
Study: 22969203

Group type: COMPARATOR
Intervention: Triple therapy (PAM): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid for 10 days
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (PAMB): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid, bismuth subcitrate 240 mg bid for 10 days
Number of subjects: 107
Study: 19118805

Group type: EXPERIMENTAL
Intervention: Relinquishing three activities
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Relinquishing five activities
Number of subjects: 206
Study: 18001671

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment for smoking cessation without nicotine replacement
Number of subjects: 74
Study: 15005584

Group type: EXPERIMENTAL
Intervention: Vitrectomy with vein decompression (Group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Vitrectomy without vein decompression (Group 2)
Number of subjects: 35
Study: 12577415

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) plus Xiaoliu Pingyi Mixture (XLPYM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 96
Study: 9529460

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control
Number of subjects: 255
Study: 7984290

Group type: EXPERIMENTAL
Intervention: Zatosetron (13 mg or 0.19 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2644533

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin) administered on days 1 and 8, starting within 36 hours after mastectomy
Number of subjects: 1275

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 1275
Study: 781229

Group type: EXPERIMENTAL
Intervention: Fenoprofen
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31418411

Group type: EXPERIMENTAL
Intervention: Pentasa + Probiotics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentasa
Number of subjects: 40
Study: 28356246

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18140

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18140
Study: 25285681

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 55

Group type: COMPARATOR
Intervention: abobotulinumtoxinA
Number of subjects: 55
Study: 23939842

Group type: EXPERIMENTAL
Intervention: Reversal and laparoscopy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard reversal
Number of subjects: 74
Study: 22075345

Group type: EXPERIMENTAL
Intervention: Local anesthetic epidurally (Group A)
Number of subjects: 17

Group type: COMPARATOR
Intervention: M relaxant (Group B)
Number of subjects: 17
Study: 19938102

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) at a standard dose of 2g per kg body weight
Number of subjects: 174
Study: 17305940

Group type: EXPERIMENTAL
Intervention: Stretching (S)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study: 15170013

Group type: EXPERIMENTAL
Intervention: COL-1492 vaginal gel containing 52.5 mg nonoxynol-9
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safer sex counselling and male condoms (provided at each visit)
Number of subjects: 0
Study: 11426000

Group type: EXPERIMENTAL
Intervention: Group 1 (50 years or younger)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group 1 women
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group 1 men
Number of subjects: 66

Group type: COMPARATOR
Intervention: Group 3 (older than 50 years with compression fracture)
Number of subjects: 66
Study: 10052024

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (4 ml saline intravenous)
Number of subjects: 94
Study: 7844226

Group type: EXPERIMENTAL
Intervention: Ménézo B2 medium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Earle's medium
Number of subjects: 0
Study: 3142396

Group type: EXPERIMENTAL
Intervention: Methyldopa (MD) 500 mg/bid, optimal dosage up to 1500 mg/bid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Labetalol (LAB) 400 mg/bid, optimal dosage up to 1200 mg/bid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Acebutolol (ACE) 400 mg/bid, optimal dosage up to 1200 mg/bid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methyldopa (MD)
Number of subjects: 63
Study: 30088008

Group type: EXPERIMENTAL
Intervention: 36-month family-based, community-centered program (n=304 pairs) consisting of 12 weekly skills-building sessions, followed by monthly coaching calls for 9 months, and a 24-month sustainability phase.
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: 36-month family-based, community-centered program (n=304 pairs)
Number of subjects: 610

Group type: COMPARATOR
Intervention: School-readiness control program (n=306 pairs) consisting of 6 sessions delivered over 36 months.
Number of subjects: 610

Group type: COMPARATOR
Intervention: School-readiness control program (n=306 pairs)
Number of subjects: 610
Study: 27623957

Group type: EXPERIMENTAL
Intervention: mesalazine 1200 mg plus a probiotic blend (Lactobacillus salivarius, Lactobacillus acidophilus, Bifidobacterium bifidus strain BGN4)
Number of subjects: 60

Group type: COMPARATOR
Intervention: mesalazine 1200 mg
Number of subjects: 60
Study: 24587759

Group type: EXPERIMENTAL
Intervention: Successful external cephalic version (ECV)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (cephalic singletons)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Previous flexed breeches
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Amniotic fluid index (AFI) of 13 or more
Number of subjects: 67
Study: 22408273

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nerve stimulation (NS)
Number of subjects: 50
Study: 20929467

Group type: EXPERIMENTAL
Intervention: High‐intensity leg‐strengthening exercises
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation and mental imagery (Control)
Number of subjects: 26
Study: 18190669

Group type: EXPERIMENTAL
Intervention: Full-ARM training (four one-to-one sessions)
Number of subjects: 231

Group type: COMPARATOR
Intervention: ARM Express (single session)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 231
Study: 15707565

Group type: EXPERIMENTAL
Intervention: Medical Abortion (MA)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Surgical Abortion (SA)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Preference for abortion method
Number of subjects: 368
Study: 11975427

Group type: EXPERIMENTAL
Intervention: TOF-tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: TOF-Guard/TOF-Watch arm board
Number of subjects: 0
Study: 10435394

Group type: COMPARATOR
Intervention: Risperidone (1 mg single oral dose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7587563

Group type: EXPERIMENTAL
Intervention: Laparoscopic TAPP procedure
Number of subjects: 102

Group type: COMPARATOR
Intervention: Shouldice repair
Number of subjects: 102
Study: 1835664

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 7004559

Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 40
Study: 31831080

Group type: EXPERIMENTAL
Intervention: TAU + training (app-based cognitive bias modification)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TAU (control group)
Number of subjects: 100
Study: 29079563

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen‐alone
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: CAC=0
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: CAC >0
Number of subjects: 1020

Group type: EXPERIMENTAL
Intervention: CAC >100
Number of subjects: 1020
Study: 26488269

Group type: EXPERIMENTAL
Intervention: MeFirst intervention (individually tailored, online educational intervention)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Control (standard CDC information factsheet on HPV vaccine)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: MeFirst intervention
Number of subjects: 661

Group type: COMPARATOR
Intervention: Control
Number of subjects: 661
Study: 22526891

Group type: EXPERIMENTAL
Intervention: Intraseptal anesthesia (ISA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Periodontal ligament anesthesia (PLA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Number of subjects: 180
Study: 21546066

Group type: EXPERIMENTAL
Intervention: Combination treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA-125 PFS status at 4 months (PFS4) in combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA-125 response in combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA-125 PFS4 in combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early CA-125 decrease
Number of subjects: 0
Study: 19178441

Group type: EXPERIMENTAL
Intervention: STIMBELT (electrical stimulation system with lumbar belt and electrodes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 17990464

Group type: EXPERIMENTAL
Intervention: Qingyi Decoction (QYD) and Glauber's salt (GS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (standard therapy without QYD and GS)
Number of subjects: 65
Study: 16392707

Group type: EXPERIMENTAL
Intervention: High-fat meal (70% energy from fat)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-fat meal (20% energy from fat)
Number of subjects: 14
Study: 12397705

Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Amlodipine besilate
Number of subjects: 4000
Study: 9803988

Group type: EXPERIMENTAL
Intervention: Zabicipril (0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zabicipril (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7897075

Group type: EXPERIMENTAL
Intervention: Aromatherapy using essential oil of lavender
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Period of rest
Number of subjects: 122
Study: 2930328

Group type: EXPERIMENTAL
Intervention: Cost-sharing plans with full catastrophic coverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-sharing plans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free-care plan
Number of subjects: 0
Study: 389121

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pharmacologically inactive dose (1 mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No disulfiram
Number of subjects: 128